{"id":"W4379283386","doi":"10.1200/jco.2023.41.16_suppl.4002","title":"Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Population; Internal medicine; Adverse effect; Atezolizumab; Oncology; Randomized controlled trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003705906,0.001020939,0.001064262,0.0003364091,0.0002792716,0.001032339,0.0005805704,0.000986831,0.004286347],"category_scores_gemma":[0.002545475,0.0003102068,0.001823674,0.0004315361,0.0004794057,0.000616422,0.0005287916,0.002387452,0.0004966534],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006085435,"about_ca_system_score_gemma":0.0006302762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003548246,"about_ca_topic_score_gemma":0.001175503,"domain_scores_codex":[0.9985245,0.001045623,0.00007172826,0.0001021648,0.0001353376,0.0001205921],"domain_scores_gemma":[0.9985262,0.0004051763,0.0005743047,0.00007102786,0.00008926537,0.0003339344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.925903,0.005476089,0.008088108,0.001119745,0.003885107,0.00007497882,0.00007129294,0.001943424,0.004476018,0.000284753,0.004684581,0.04399302],"study_design_scores_gemma":[0.6584327,0.260839,0.0589072,0.0002682735,0.006039407,0.0004518042,0.0001080402,0.00359205,0.003180012,0.0006053084,0.007497078,0.00007900286],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747311,0.008978297,0.0008139539,0.00114494,0.0002142898,0.002167347,0.006377054,0.00009337225,0.005479788],"genre_scores_gemma":[0.9850422,0.002143046,0.0009489906,0.001063839,0.0002015358,0.00249079,0.006201063,0.00001982778,0.001888825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004286347,"threshold_uncertainty_score":0.0195989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0569313940728409,"score_gpt":0.3855829067397852,"score_spread":0.3286515126669443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}